You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival
|
|---|---|
| Published in |
Radiation Oncology, June 2017
|
| DOI | 10.1186/s13014-017-0837-5 |
| Pubmed ID | |
| Authors |
Carla Freiberger, Vanessa Berneking, Thomas-Alexander Vögeli, Ruth Kirschner-Hermanns, Michael J. Eble, Michael Pinkawa |
| Abstract |
The aim of this study was to evaluate the long-term prognostic significance of rising PSA levels, particularly focussing on overall survival. Two hundred ninety-five patients with localized prostate cancer were either treated with low-dose-rate (LDR) brachytherapy with I-125 seeds as monotherapy (n = 94; 145Gy), high-dose-rate (HDR) brachytherapy with Ir-192 as a boost to external beam RT (n = 66; 50.4Gy in 1.8Gy fractions EBRT + 18Gy in 9Gy fractions HDR) or EBRT alone (70.2Gy in 1.8Gy fractions; n = 135). "PSA bounce" was defined as an increase of at least 0.2 ng/ml followed by spontaneous return to pre-bounce level or lower, biochemical failure was defined according to the Phoenix definition. Median follow-up after the end of radiotherapy was 108 months. A PSA bounce showed to be a significant factor for biochemical control (BC) and overall survival (OS) after ten years (BC10 of 83% with bounce vs. 34% without, p < 0.01; OS10 of 82% with bounce vs. 59% without bounce, p < 0.01). The occurrence of a bounce, a high nadir and the therapy modality (LDR-BT vs. EBRT and HDR-BT + EBRT vs. EBRT) proved to be independent factors for PSA recurrence in multivariate Cox regression analysis. A bounce was detected significantly earlier than a PSA recurrence (median 20 months vs. 32 months after RT; p < 0.01; median PSA doubling time 5.5 vs. 5.0 months, not significant). PSA doubling time was prognostically significant in case of PSA recurrence (OS10 of 72% vs. 36% with PSA doubling time ˃ 5 months vs. ≤ 5 months; p < 0.01). Rising PSA levels within the first two years can usually be classified as a benign PSA bounce, with favourable recurrence-free and overall survival rates. PSA doubling time is an important predictor for overall survival following the diagnosis of a recurrence. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Cyprus | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 13% |
| Researcher | 4 | 13% |
| Student > Postgraduate | 4 | 13% |
| Student > Master | 4 | 13% |
| Student > Doctoral Student | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 8 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 44% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Unspecified | 1 | 3% |
| Economics, Econometrics and Finance | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 11 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2019.
All research outputs
#7,349,898
of 23,905,714 outputs
Outputs from Radiation Oncology
#366
of 2,129 outputs
Outputs of similar age
#113,343
of 320,055 outputs
Outputs of similar age from Radiation Oncology
#5
of 30 outputs
Altmetric has tracked 23,905,714 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,129 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,055 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.